SEC insider transactions · retrieved 2026-09-07 · 2026 Q2: filings in this completed quarter; not a live transaction feed
Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.
Transaction rows by code · counts, not monetary totals
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift
0 matching transaction rows.
No matching transaction rows in the covered quarter. This does not establish that no insider transactions occurred.
Identity & relationships
Wikidata structured data · retrieved 2026-09-07 · 1611 unambiguous CIK-linked entities; coverage is incomplete
These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.
SEC issuer · 0000812796SOLIGENIX, INC.
No parent relationship is available in this import; this is not proof of independence.
SOLIGENIX, INC. · former SEC name · 2009-09-30 to 2026-08-07
DOR BIOPHARMA INC · former SEC name · 2002-04-01 to 2009-09-29
ENDOREX CORP · former SEC name · 1996-09-16 to 2001-10-24
IMMUNOTHERAPEUTICS INC · former SEC name · 1995-08-08 to 1996-04-30
Revenue in constant purchasing power
USD revenue expressed in 2026-07 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.